Clinical Trial Detail

NCT ID NCT02420912
Title Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Ibrutinib + Nivolumab

Age Groups: adult

No variant requirements are available.